An intranasal influenza vaccine for the prevention of influenza in healthy children was cost-effective.

M a i n c o s t a n d o u t c o m e m e a s u r e s Cost per febrile influenza-like illness (ILI) day avoided. A break-even analysis was also done to calculate the vaccine-plus-administration cost below which its use would be cost saving. Per-child cost-effectiveness analyses were done separately for an individualbased and group-based vaccination delivery scenario from the societal and third-party payer perspectives. Costs were assessed in U.S. dollars and were discounted at a rate of 3% in year 2.